[1]薛进华 叶超 毛露 Dirk Hermann 陈艾东.活性氧引起缺氧诱导因子1活化参与肺动脉高压血管重塑的分子机制[J].心血管病学进展,2020,(8):844-846.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.015]
 XUE Jinhua,YE Chao,MAO Lu,et al.Molecular Mechanism of Hypoxia Inducible Factor-1 Activation Induced by Reactive Oxygen Species in Vascular Remodeling of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(8):844-846.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.015]
点击复制

活性氧引起缺氧诱导因子1活化参与肺动脉高压血管重塑的分子机制()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年8期
页码:
844-846
栏目:
综述
出版日期:
2020-08-25

文章信息/Info

Title:
Molecular Mechanism of Hypoxia Inducible Factor-1 Activation Induced by Reactive Oxygen Species in Vascular Remodeling of Pulmonary Hypertension
作者:
薛进华12 叶超3 毛露 4 Dirk Hermann 2 陈艾东 23
(1.心脑血管疾病研究中心,赣南医学院,江西 赣州 341000 ;2.神经生物学研究中心,杜伊斯堡-埃森大学,德国 埃森45122;3.心血管疾病靶向干预重点实验室,南京医科大学,江苏 南京 211166 ;4.东南大学附属中大医院,东南医科大学,江苏 南京210096)
Author(s):
XUE Jinhua12 YE Chao3 MAO Lu4 Dirk Hermann2 CHEN Aidong23
(1.Research Center for Cardiovascular and Cerebrovascular Diseases,Gannan Medical College,Ganzhou 341000,Jiangxi,China;4.Center for Neurobiology,Duisburg-Essen University,Essen 45122,Germany; 2.Key Laboratory of Targeting Interventions for Cardiovascular Diseases,Nanjing Medical University,Nanjing 211166,Jiangsu,China; 3.Zhongda Hospital Affiliated to Southeast University,Southeast Medical University,Nanjing 210096,Jiangsu,China )
关键词:
肺动脉高压活性氧缺氧诱导因子1血管重塑
Keywords:
Pulmonary hypertension Reactive oxygen species Hypoxia inducible factor 1 Vascular remodeling
DOI:
10.16806/j.cnki.issn.1004-3934.2020.08.015
摘要:
肺动脉高压的特点是血管收缩和血管平滑肌细胞增生,导致肺动脉血管的病理性重塑。活性氧介导缺氧诱导因子1的活化,通过一系列的下游细胞信号,引起肺血管的异常调节,造成管壁肥大和增厚,在肺动脉高压的血管重塑中起关键作用。肺动脉高压时,针对活性氧和缺氧诱导因子1的干预,以调节氧化还原信号为中心的治疗方法,有望成为本病治疗新的策略和重要靶点,现将就此做一详细阐述。
Abstract:
Pulmonary hypertension (PH) is characterized by vasoconstriction and proliferation of vascular smooth muscle cells,leading to pathological remodeling of pulmonary arteries. ROS mediates the activation of hypoxia inducible factor-1 (HIF-1). Through a series of downstream cell signals,it causes abnormal regulation of pulmonary vessels,resulting in hypertrophy and thickening of the vessel wall,which plays a key role in the vascular remodeling of PH.For the intervention of ROS and HIF-1 in PH,the treatment method centering on the regulation of redox signal is expected to become a new strategy and an important target for the treatment of this disease. This paper will elaborate on these in detail.

参考文献/References:

[1].Marushchak M,Maksiv K,Krynytska I,et al. Glutathione antioxidant system of mphocytes in the blood of patients in a setting of concomitant chronic obstructive?pulmonary?disease and arterial?hypertension[J]. Pol Merkur Lekarski,2019,47(281):177-182.
[2].Zimmer A,Teixeira RB,Bonetto JHP,et al. Role of inflammation,oxidative stress,and autonomic nervous system activation during the development of right and left cardiac remodeling in experimental?pulmonary?arterial?hypertension[J]. Mol Cell Biochem,2020,464(1-2):93-109.
[3].Zhu N,Xiang Y,Zhao X,et al. Thymoquinone suppresses platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation,migration and neointimal formation[J]. J Cell Mol Med,2019,23(12):8482-8492.
[4].Yuan XM,Zhuan B,Li P,et al. Expression of nicotinamide adenine dinucleotide phosphate-reduced oxidase-4/reactive oxygen species and cystathionine-γ-lyase/hydrogen sulfide in patients with chronic obstructive?pulmonary?disease-related?pulmonary hypertension[J]. Zhonghua Nei Ke Za Zhi,2019,58(10):770-776.
[5].张国振,何庆.活性氧对高原性肺动脉高压的影响[J].心血管病学进展,2018,39(4):576-579.
[6].Marushchak M,Maksiv K,Krynytska I. The specific features of free radical oxidation in patients with chronic obstructive?pulmonary?disease and arterial?hypertension[J]. Pol Merkur Lekarski,2019,47(279):95-98.
[7].Barton M,Meyer MR,Prossnitz ER.Nox1 downregulators:a new class of therapeutics[J]. Steroids,2019,152(108):94-103.
[8].Suresh K,Servinsky L,Jiang H,et al. Regulation of mitochondrial fragmentation in microvascular endothelial cells isolated from the SU5416/hypoxia model of?pulmonary?arterial?hypertension[J]. Am J Physiol Lung Cell Mol Physiol. 2019,317(5):L639-L652.
[9].Daneva Z,Laubach VE,Sonkusare SK. Novel regulators and targets of redox signaling in?pulmonary?vasculature[J]. Curr Opin Physiol,2019,9(4):87-93.
[10].Prasad K. AGE-RAGE stress in the pathophysiology of?pulmonary hypertension?and its treatment[J]. Int J Angiol,2019,28(2):71-79.
[11].Wu YC,Wang WT,Lee SS,et al. Glucagon-like peptide-1 receptor agonist attenuates autophagy to ameliorate?pulmonary?arterial?hypertension?through Drp1/NOX- and Atg-5/Atg-7/Beclin-1/LC3β pathways[J]. Int J Mol Sci,2019,20(14):3435.
[12].Allawzi A,Elajaili H,Redente EF,et al. Oxidative toxicology of bleomycin:role of the extracellular redox environment[J]. Curr Opin Toxicol,2019,13(2):68-73.
[13].Meng Z,Li HY,Si CY,et al. Asiatic acid inhibits cardiac fibrosis throughNrf2/HO-1 and TGF-β1/Smads signaling pathways in spontaneous?hypertension?rats[J]. Int Immunopharmacol,2019,74:105712.
[14].Wu MM,Liang C,Yu XD,et al. Lovastatin attenuates?hypertension?induced by renal tubule-specific knockout of ATP-binding cassette transporter A1,by inhibiting epithelial sodium channels[J]. Br J Pharmacol,2019,176(18):3695-3711.
[15].Zhu J,Kovacs L,Han W,et al. Reactive oxygen species-dependent calpain activation contributes to airway and?pulmonary?vascular remodeling in chronic obstructive?pulmonary?disease[J]. Antioxid Redox Signal,2019,31(12):804-818.
[16].Novelli EM,Little-Ihrig L,Knupp HE,et al. Vascular TSP1-CD47 signaling promotes sickle cell-associated arterial vasculopathy and?pulmonary hypertension?in mice[J]. Am J Physiol Lung Cell Mol Physiol,2019,316(6):L1150-L1164.
[17].Sch JC,Suresh K,Shimoda LA. Regulation of smooth muscle cell proliferation by NADPH oxidases in?pulmonary hypertension[J]. Antioxidants (Basel),2019,8(3):56.
[18].De Jesus DS,DeVallance E,Li Y,et al. Nox1/Ref-1-mediated activation of CREB promotes Gremlin1-driven endothelial cell proliferation and migration[J]. Redox Biol,2019,1011(28):38-47.
[19].Truong L,Zheng YM,Wang YX. Mitochondrial Rieske iron-sulfur protein in?pulmonary?artery smooth muscle:A key primary signaling molecule in?pulmonary hypertension[J]. Arch Biochem Biophys,2019,664:68-75.
[20].Qi L,Lv T,Cheng Y,et al. Fasudil?dichloroacetate?(FDCA),an orally available agent with potent therapeutic efficiency on monocrotaline-induced?pulmonary?arterial?hypertension?rats[J]. Bioorg Med Chem Lett,2019,29(14):1812-1818.

相似文献/References:

[1]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
 MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(8):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[2]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
 ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(8):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[3]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
 WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(8):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[4]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
 WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[5]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
 DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(8):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[6]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
 ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(8):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[7]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
 ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(8):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[8]韩柯,孟祥光,赵育洁.趋化因子及其受体在肺动脉高压中的研究进展[J].心血管病学进展,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
 HAN Ke,MENG Xiangguang,ZHAO Yujie.Chemokines and Their Receptors in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(8):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
[9]刘超 曲杰 王明娟 徐倩 范彦芳 周晓慧 单伟超.肺动脉高压对扩张型心肌病预后的影响[J].心血管病学进展,2020,(4):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
 LIU ChaoQU JieWANG MingjuanXU QianFAN YanfangZHOU XiaohuiSAN Weichao.The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(8):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
[10]向杰 刘明鑫 张伟 黄从新.基于生物信息学分析探究肺动脉高压关键基因和通路[J].心血管病学进展,2020,(4):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
 Xiang JieLiu MingxinZhang WeiHuang Congxin.Bioinformatics Analysis of Key Genes and Pathways in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(8):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金面上项目( 31571168,81571246);国家公派留学基金(20173059);中国博士后基金(2016M591750和2017T100320)
通讯作者:陈艾东,E-mail:aidongchen@njmu.edu.cn
收稿时间:2020-01-24
更新日期/Last Update: 2020-11-02